{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:52:06Z","timestamp":1777521126126,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Education Board of Medical Specialties","award":["071218146"],"award-info":[{"award-number":["071218146"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10384-021-00895-9","type":"journal-article","created":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:02:43Z","timestamp":1643414563000},"page":"151-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-910X","authenticated-orcid":false,"given":"Utku","family":"Furuncuoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asl\u0131","family":"Vural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alev","family":"Kural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail Umut","family":"Onur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadime Ulviye","family":"Yigit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"key":"895_CR1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841\u20134.","journal-title":"Nature"},{"key":"895_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S1084-2756(03)00119-2","volume":"8","author":"LEH Smith","year":"2003","unstructured":"Smith LEH. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8:469\u201373.","journal-title":"Semin Neonatol"},{"key":"895_CR3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/bjophthalmol-2011-300654","volume":"96","author":"MW Stewart","year":"2012","unstructured":"Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96:1157\u20138.","journal-title":"Br J Ophthalmol"},{"key":"895_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171\u201385.","journal-title":"Angiogenesis"},{"key":"895_CR5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3061","volume":"142","author":"WM Fierson","year":"2018","unstructured":"Fierson WM. Ophthalmology AA of screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018;142: e20183061.","journal-title":"Pediatrics"},{"key":"895_CR6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity. Results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684\u201396.","journal-title":"Arch Ophthalmol"},{"key":"895_CR7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","volume":"256","author":"CY Huang","year":"2018","unstructured":"Huang CY, Lien R, Wang NK, Chao AN, Chen KJ, Chen TL, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2018;256:479\u201387.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"895_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000364809","volume":"53","author":"AG Salman","year":"2015","unstructured":"Salman AG, Said AM. Structural, visual and refractive outcomes of intravitreal aflibercept injeciton in high-risk prethreshold type 1 retinopathy of prematurity. Ophthal Res. 2015;53:15\u201320.","journal-title":"Ophthal Res"},{"key":"895_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/00365510260296492","volume":"62","author":"K Werther","year":"2002","unstructured":"Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance in VEGF in various leucocytes and platelets. Scand J Clin Lab Invest. 2002;62:343\u201350.","journal-title":"Scand J Clin Lab Invest"},{"key":"895_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/172460080101600202","volume":"16","author":"R Dittadi","year":"2001","unstructured":"Dittadi R, Meo S, Fabris F, Gasparini G, Contri D, Medici M, et al. Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers. 2001;16:87\u201396.","journal-title":"Int J Biol Markers"},{"key":"895_CR11","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.ophtha.2009.04.026","volume":"116","author":"T Sato","year":"2009","unstructured":"Sato T, Kusaka S, Shimojo H, Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology. 2009;116:2165\u20139.","journal-title":"Ophthalmology"},{"key":"895_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.11622\/smedj.2013246","volume":"54","author":"A Peirovifar","year":"2013","unstructured":"Peirovifar A, Gharehbaghi MM, Gharabaghi PM, Sadeghi K. Vascular endothelial growth factor and insulin-like growth factor-1 in preterm infants with retinopathy of prematurity. Singapore Med J. 2013;54:709\u201312.","journal-title":"Singapore Med J"},{"key":"895_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H, Kuno N, Imoto K, Shima CI, et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327\u201333.","journal-title":"Am J Ophthalmol"},{"key":"895_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","volume":"133","author":"WC Wu","year":"2015","unstructured":"Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015;133:391\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"895_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1755-3768.2012.02469.x","volume":"91","author":"R Hoerster","year":"2013","unstructured":"Hoerster R, Muether P, Dahlke C, Mehler K, Oberth\u00fcr A, Kirchhof B, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 2013;91:74\u20135.","journal-title":"Acta Ophthalmol"},{"key":"895_CR16","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ajo.2014.06.009","volume":"158","author":"X Wang","year":"2014","unstructured":"Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol. 2014;158:738\u201344.","journal-title":"Am J Ophthalmol"},{"key":"895_CR17","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1111\/aos.12604","volume":"93","author":"C Zehetner","year":"2015","unstructured":"Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, et al. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial. Acta Ophthalmol. 2015;93:e154\u20139.","journal-title":"Acta Ophthalmol"},{"key":"895_CR18","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1097\/IAE.0000000000002004","volume":"38","author":"T Hirano","year":"2018","unstructured":"Hirano T, Toriyama Y, Iesato Y, Imai A, Murata T. Changes in plasma vascular endothelial growth factor level after intravitreal injection of bevacizumab, aflibercept or ranibizumab for diabetic macular edema. Retina. 2018;38:1801\u20138.","journal-title":"Retina"},{"key":"895_CR19","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, Fleck B, Reynolds JD, Chiang MF, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394:1551\u20139.","journal-title":"Lancet"},{"key":"895_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","volume":"22","author":"KA Kennedy","year":"2018","unstructured":"Kennedy KA, Mintz-Hittner HA. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS. 2018;22:61-65.e1.","journal-title":"J AAPOS"},{"key":"895_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien R, Yu MH, Hsu KH, Liao PJ, Chen YP, Lai CC, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PloS One. 2016;11: e0148019.","journal-title":"PloS One"},{"key":"895_CR22","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137: e20153218.","journal-title":"Pediatrics"},{"key":"895_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","volume":"254","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Jiang Y, Bai Y, Wen J, Chen L. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2016;254:31\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"895_CR24","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179\u201382.","journal-title":"Ophthalmology"},{"key":"895_CR25","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1517\/14712598.5.1.S37","volume":"5","author":"D Ternant","year":"2005","unstructured":"Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005;5:S37\u201347.","journal-title":"Expert Opin Biol Ther"},{"key":"895_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/IAE.0000000000002566","volume":"40","author":"DV Do","year":"2020","unstructured":"Do DV, Rhoades W, Nguyen QD. Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration. Retina. 2020;40:643\u20137.","journal-title":"Retina"},{"key":"895_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2018-000185","volume":"4","author":"PK Kaiser","year":"2019","unstructured":"Kaiser PK, Kodjikian L, Korobelnik JF, Winkler J, Torri A, Zeitz O, et al. Systemic pharmacokinetic\/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases. BMJ Open Ophthalmol. 2019;4: e000185.","journal-title":"BMJ Open Ophthalmol"},{"key":"895_CR28","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1167\/iovs.14-15842","volume":"56","author":"L Kong","year":"2015","unstructured":"Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab and its effects on serum vegf and igf-1 in infants with retinopathy of prematurity. Investig Ophthalmol Vis Sci. 2015;56:956\u201361.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"895_CR29","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","volume":"98","author":"RL Avery","year":"2014","unstructured":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular amd. Br J Ophthalmol. 2014;98:1636\u201341.","journal-title":"Br J Ophthalmol"},{"key":"895_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s41038-017-0090-z","volume":"5","author":"TL Palmieri","year":"2017","unstructured":"Palmieri TL. Children are not little adults: blood transfusion in children with burn injury. Burns Trauma. 2017;5:24.","journal-title":"Burns Trauma"},{"key":"895_CR31","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.preteyeres.2010.04.003","volume":"29","author":"A Laude","year":"2010","unstructured":"Laude A, Tan LE, Wilson CG, Lascaratos G, Elashry M, Aslam T, et al. Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics. Progr Retinal Eye Res. 2010;29:466\u201375.","journal-title":"Progr Retinal Eye Res"},{"key":"895_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","volume":"11","author":"LG Quintanilla","year":"2019","unstructured":"Quintanilla LG, Rodr\u00edguez AL, Mart\u00ednez MG, Garcia CM, Maronas O, Sanjuan VM, et al. Pharmacokinetics of \u0131ntravitreal anti-VEGF drugs in age-related macular degeneration. Pharmaceutics. 2019;11:365.","journal-title":"Pharmaceutics"},{"key":"895_CR33","first-page":"2803","volume":"15","author":"H Kim","year":"2009","unstructured":"Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis. 2009;15:2803\u201312.","journal-title":"Mol Vis"},{"key":"895_CR34","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.101113998","volume":"98","author":"A Hellstrom","year":"2001","unstructured":"Hellstrom A, Perruzzi C, Ju M, Engstrom E, Hard AL, Liu JL, et al. Low IGF-1 suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA. 2001;98:5804\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"895_CR35","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1542\/peds.112.5.1016","volume":"112","author":"A Hellstr\u00f6m","year":"2003","unstructured":"Hellstr\u00f6m A, Engstr\u00f6m E, H\u00e5rd AL, Wikland KA, Carlsson B, Niklasson A, et al. Postnatal serum insulin-like growth factor i deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics. 2003;112:1016\u201320.","journal-title":"Pediatrics"},{"key":"895_CR36","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1542\/peds.2005-1926","volume":"117","author":"C L\u00f6fqvist","year":"2006","unstructured":"L\u00f6fqvist C, Engstr\u00f6m E, Sigurdsson J, Hard AL, Niklasson A, Ewald U, et al. Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulin-like growth factor-1 deficit. Pediatrics. 2006;117:1930\u20138.","journal-title":"Pediatrics"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-021-00895-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-021-00895-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-021-00895-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T13:03:46Z","timestamp":1645967026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-021-00895-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,29]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["895"],"URL":"https:\/\/doi.org\/10.1007\/s10384-021-00895-9","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,29]]},"assertion":[{"value":"11 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"U. Furuncuoglu, None; A. Vural, None; A. Kural, None; I. U. Onur, None; F. U. Yigit, None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}